Skip to main content
NewslettersWatchlist

Bioaffinity Technologies Inc(BIAF-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.44
Day High2.68
Open:2.46
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer
Business Wire
bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium
Business Wire
bioAffinity Technologies to Ring Nasdaq Closing Bell Today
Business Wire
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
Business Wire
bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
Business Wire
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
Business Wire
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
Business Wire
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
PR Newswire
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
Business Wire
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
Business Wire
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
Business Wire
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
Business Wire
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
Business Wire
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
Business Wire
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
Business Wire
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
Business Wire
bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M
Business Wire
bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE
PR Newswire
WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering
Business Wire
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering

Profile

bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.